Navigation Links
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Date:6/20/2008

cles of oral melphalan (M) plus prednisone (P) or MP plus VELCADE. Patients received M (9 mg/m2) plus P (60 mg/m2) daily for four days every 6 weeks or the same MP schedule with bortezomib (1.3 mg/m2) IV on days 1, 4, 8, 11, 22, 25, 29 and 32 of every 6 week cycle for 4 cycles then once weekly for 4 weeks on days 1, 8, 22 and 29 of every 6 week cycle for 5 additional cycles. Antiviral prophylaxis was recommended for patients on the VELCADE study arm. Time-to-progression (TTP) was the primary efficacy endpoint. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were secondary endpoints. A total of 682 patients were randomized: 338 to receive MP and 344 to receive the combination of bortezomib plus MP. The median age of patients for both groups was 71 years. Demographics and baseline disease characteristics were similar between the two groups.

The safety profile of VELCADE in combination with MP is consistent with the known safety profiles of both VELCADE and MP.

In VISTA, the most commonly reported adverse events for VELCADE in combination with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% v
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Japan Approves CyberKnife System for Extracranial Use
2. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
3. FDA Approves Cymbalta(R) for the Management of Fibromyalgia
4. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
5. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
6. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
7. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
8. FDA Approves Health Claim for Brown Rice
9. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
10. FDA approves HeartMate II mechanical heart pump for heart-failure patients
11. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
(Date:9/1/2015)... Melbourne, Florida (PRWEB) , ... ... ... Association of Professional Background Screeners (NAPBS®) has announced that Edge Information ... audit conducted by the Background Screening Credentialing Council (BSCC). , “Achieving ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... real-time monitoring and analysis of pet vital signs and activity, today announced its ... one of the most popular and widely-adopted veterinary hospital Practice Management Software packages ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... government entities, announced today that it has hired Scott Sanderson, an experienced business ... this capacity, Sanderson will be responsible for establishing and managing new client relationships ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, ... that followed men and women for 19 years and found that, among those who ... take multivitamins. , The report is part of the September 2015 issue of “Natural ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... Crucell N V’s Rabies monoclonal antibody (mAb) product has ... months after launching// a similar study in the US. ... antibody product for the post-exposure prophylaxis of rabies, using ... I study is closely linked to the initial phase ...
... the first patient in a new phase II/III clinical ... or HHT) in patients with Chronic Myeloid Leukemia (CML) ... two or more prior tyrosine kinase inhibitors (TKIs). ... ongoing registration-directed clinical trial in CML patients with the ...
... Mental Hygiene is planning a campaign to encourage men at ... the World Health Organization’s endorsement// of the procedure as an ... States, “New York City remains the epicenter of the AIDS ... in an interview. Referring to H.I.V., he said, “In some ...
... constipation affects 15 to 20 percent of the U.S. ... in which muscles used// for bowel movements do not ... relieved now, as the new research shows biofeedback treatment ... better than standard treatment of laxatives, diet and exercise ...
... rates of amphetamine and cocaine use by young adults significantly ... the greatest risk// , according to a research. ,In ... UT Southwestern physicians examined more than 8,300 stroke patients – ... 400 Texas hospitals in the years 2000 through 2003. ...
... and Allied Science (RINPAS), one of India's premier mental hospitals, ... to reach out to more people. ,"The ... with the institute," RINPAS director P.K. Chakravarty said Thursday. ... as hospital inmates. ,RINPAS was set up in ...
Cached Medicine News:Health News:Crucell's Rabies MAb Enters Phase I Trial in India 2Health News:New York City Plans to Promote Circumcision 2Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Amphetamine, Cocaine Use Increase Risk of Stroke in Young Adults 2
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. ... U.S. Representatives Michael C. Burgess , M.D., and ... the 21 st Century Cures Act, bipartisan legislation ... the United States Senate. ... Sciences members, department chairs, center directors, and leading researchers ...
(Date:9/1/2015)... 2015   Alpha Imaging LLC , a leading distributor of ... announced today that they have been awarded exclusive rights to represent ... Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales and ... Ohio , Indiana , Pennsylvania ... , West Virginia , Delaware ...
Breaking Medicine Technology:Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2
... 21, 2011 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the ... leading specialty pharmaceutical company focusing on the development, manufacturing, ... China, today announced that it plans to release its ... the market close on March 25, 2011. ...
... today announced that its Board of Directors has appointed Dirk ... immediately.  Mr. Allison has been the interim CEO of the ... about joining CCS Medical as its President and Chief Executive ... markets and I look forward to continuing our growth in ...
Cached Medicine Technology:Tongjitang Chinese Medicines Company to Announce Fourth Quarter and Full Year 2010 Financial Results 2
Enzyme immunoassay for the quantitative determination of IgG autoantibodies against type IV collagen of glomerular or alveolar basement membrane (GBM) in serum and plasma....
... immunosorbent assay method for the semi-quantitative ... GBM in human serum. The results ... as an aid in the diagnosis ... of anti-GBM antibodies including Goodpastures Syndrome. ...
... intimately involved in the control of the ... tissues, which synthesize and secrete male and ... circulating FSH is controlled by these sex ... FSH Quantitative Test Kit is based ...
... Class II Direct to High Res SSP kits provide ... single tray. Locus specific typing on a single tray ... Straight from genomic DNA to high resolution results, ... level typing with a single tray , Unique reaction ...
Medicine Products: